Pharmacogenetics in IBS: Update and Impact of GWAS Studies in Drug Targets and Metabolism

Overview

Journal Expert Opin Drug Metab Toxicol

Publisher Informa Healthcare

Specialties Endocrinology
Pharmacology
Toxicology

Date 2024 May 24

PMID 38785066

Authors

Michael Camilleri

Kara Jencks

Affiliations

Soon will be listed here.

Abstract

Introduction: Medications are frequently prescribed for patients with irritable bowel syndrome (IBS) or disorders of gut brain interaction. The level of drug metabolism and modifications in drug targets determine medication efficacy to modify motor or sensory function as well as patient response outcomes.

Areas Covered: The literature search included PubMed searches with the terms: pharmacokinetics, pharmacogenomics, epigenetics, clinical trials, irritable bowel syndrome, disorders of gut brain interaction, and genome-wide association studies. The main topics covered in relation to irritable bowel syndrome were precision medicine, pharmacogenomics related to drug metabolism, pharmacogenomics related to mechanistic targets, and epigenetics.

Expert Opinion: Pharmacogenomics impacting drug metabolism [CYP 2D6 (cytochrome P450 2D6) or 2C19 (cytochrome P450 2C19)] is the most practical approach to precision medicine in the treatment of IBS. Although there are proof of concept studies that have documented the importance of genetic modification of transmitters or receptors in altering responses to medications in IBS, these principles have rarely been applied in patient response outcomes. Genome-wide association (GWAS) studies have now documented the association of symptoms with genetic variation but not the evaluation of treatment responses. Considerably more research, particularly focused on patient response outcomes and epigenetics, is essential to impact this field in clinical medicine.

References

Li Q, Winston J, Sarna S . Developmental origins of colon smooth muscle dysfunction in IBS-like rats. Am J Physiol Gastrointest Liver Physiol. 2013; 305(7):G503-12. PMC: 3798719. DOI: 10.1152/ajpgi.00160.2013. View

Keck S, Galati-Fournier V, Kym U, Moesch M, Usemann J, Muller I . Lack of Mucosal Cholinergic Innervation Is Associated With Increased Risk of Enterocolitis in Hirschsprung's Disease. Cell Mol Gastroenterol Hepatol. 2021; 12(2):507-545. PMC: 8258990. DOI: 10.1016/j.jcmgh.2021.03.004. View

Nagel M, Watanabe K, Stringer S, Posthuma D, van der Sluis S . Item-level analyses reveal genetic heterogeneity in neuroticism. Nat Commun. 2018; 9(1):905. PMC: 5834468. DOI: 10.1038/s41467-018-03242-8. View

Montano J, Calavia M, Garcia-Suarez O, Suarez-Quintanilla J, Galvez A, Perez-Pinera P . The expression of ENa(+)C and ASIC2 proteins in Pacinian corpuscles is differently regulated by TrkB and its ligands BDNF and NT-4. Neurosci Lett. 2009; 463(2):114-8. DOI: 10.1016/j.neulet.2009.07.073. View

Zhang Y, Li Y, Hao Z, Li X, Bo P, Gong W . Association of the Serotonin Receptor 3E Gene as a Functional Variant in the MicroRNA-510 Target Site with Diarrhea Predominant Irritable Bowel Syndrome in Chinese Women. J Neurogastroenterol Motil. 2016; 22(2):272-81. PMC: 4819866. DOI: 10.5056/jnm15138. View

Hong S, Zheng G, Wiley J . Epigenetic regulation of genes that modulate chronic stress-induced visceral pain in the peripheral nervous system. Gastroenterology. 2014; 148(1):148-157.e7. PMC: 4274248. DOI: 10.1053/j.gastro.2014.09.032. View

Wu Y, Murray G, Byrne E, Sidorenko J, Visscher P, Wray N . GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal disorders and depression. Nat Commun. 2021; 12(1):1146. PMC: 7895976. DOI: 10.1038/s41467-021-21280-7. View

Swathy B, Saradalekshmi K, Nair I, Nair C, Banerjee M . Pharmacoepigenomic responses of antipsychotic drugs on pharmacogenes are likely to be modulated by miRNAs. Epigenomics. 2017; 9(6):811-821. DOI: 10.2217/epi-2016-0181. View

Smith D, Sadler M, Altman R . Promises and challenges in pharmacoepigenetics. Camb Prism Precis Med. 2023; 1:e18. PMC: 10406571. DOI: 10.1017/pcm.2023.6. View

10.

Camilleri M, Katzka D . Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012; 302(10):G1075-84. PMC: 3362100. DOI: 10.1152/ajpgi.00537.2011. View

11.

Rao A, Wong B, Camilleri M, Odunsi-Shiyanbade S, McKinzie S, Ryks M . Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 2010; 139(5):1549-58, 1558.e1. PMC: 3189402. DOI: 10.1053/j.gastro.2010.07.052. View

12.

Yamada K, Hattori E, Iwayama Y, Ohnishi T, Ohba H, Toyota T . Distinguishable haplotype blocks in the HTR3A and HTR3B region in the Japanese reveal evidence of association of HTR3B with female major depression. Biol Psychiatry. 2006; 60(2):192-201. DOI: 10.1016/j.biopsych.2005.11.008. View

13.

Fukudo S . Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol. 2007; 42 Suppl 17:48-51. DOI: 10.1007/s00535-006-1942-7. View

14.

Wouters M, Lambrechts D, Knapp M, Cleynen I, Whorwell P, Agreus L . Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. Gut. 2013; 63(7):1103-11. DOI: 10.1136/gutjnl-2013-304570. View

15.

Blagec K, Swen J, Koopmann R, Cheung K, Crommentuijn-van Rhenen M, Holsappel I . Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries. PLoS One. 2022; 17(6):e0268534. PMC: 9176797. DOI: 10.1371/journal.pone.0268534. View

16.

Chang W, Yang Y, She M, Tu C, Lee T, Wu M . 5-HT receptor-dependent intestinal neurite outgrowth contributes to visceral hypersensitivity in irritable bowel syndrome. Lab Invest. 2022; 102(9):1023-1037. PMC: 9420680. DOI: 10.1038/s41374-022-00800-z. View

17.

Collins F, Varmus H . A new initiative on precision medicine. N Engl J Med. 2015; 372(9):793-5. PMC: 5101938. DOI: 10.1056/NEJMp1500523. View

18.

Parker C, Naliboff B, Shih W, Presson A, Videlock E, Mayer E . Negative Events During Adulthood Are Associated With Symptom Severity and Altered Stress Response in Patients With Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2019; 17(11):2245-2252. PMC: 6609507. DOI: 10.1016/j.cgh.2018.12.029. View

19.

Lesch K, Bengel D, Heils A, Sabol S, Greenberg B, Petri S . Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996; 274(5292):1527-31. DOI: 10.1126/science.274.5292.1527. View

20.

Drossman D, Tack J, Ford A, Szigethy E, Tornblom H, Van Oudenhove L . Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. Gastroenterology. 2017; 154(4):1140-1171.e1. DOI: 10.1053/j.gastro.2017.11.279. View